Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 15, 2017

BioPharm International

  • BioPharm International-05-15-2017
  • Volume 2017 eBook
  • Issue 1

Gearing Up for Biosimilars

Author(s)Tim Sturgeon

Contract manufacturers prepare for anticipated biosimilars manufacturing demands through expansion and acquisition.

Compared to traditional small-molecule generics, the R&D costs and development times for biosimilars are significantly greater. With demand for services in the biosimilars space set to soar, many contract development and manufacturing organizations are increasing their capabilities in this field.  Expansions including in-house development, partnerships and joint ventures, or bolt-on acquisitions are summarized.

 

Download BioPharm International's

2017 Outsourcing Resources eBook

.

 

 

 

 


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.